Clinical Trial Update: A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing BMS-986365 to investigator's choice therapy in metastatic castration-resistant prostate cancer, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• BMS-986365

Snippet

Sponsor: Celgene | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 3 | Status: RECRUITING